Journal article
Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial
Abstract
BACKGROUND: The National Cancer Institute of Canada Clinical Trials Group CO.17 study showed that patients with advanced colorectal cancer had improved overall survival when cetuximab, an epidermal growth factor receptor-targeting antibody, was given in addition to best supportive care. We conducted a cost-effectiveness analysis using prospectively collected resource utilization and health utility data for patients in the CO.17 study who …
Authors
Mittmann N; Au H-J; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J
Journal
Journal of the National Cancer Institute, Vol. 101, No. 17, pp. 1182–1192
Publisher
Oxford University Press (OUP)
Publication Date
September 2, 2009
DOI
10.1093/jnci/djp232
ISSN
0027-8874
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBiomarkers, TumorCanadaCetuximabColorectal NeoplasmsConfidence IntervalsCost-Benefit AnalysisDrug CostsErbB ReceptorsHealth Care CostsHealth ResourcesHumansMutationPatient SelectionProspective StudiesProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Quality-Adjusted Life YearsResearch DesignSurvival Analysisras Proteins